Related Experiment Video
Updated: Jan 16, 2026
Optimizing Isolation and Purification of Murine Glomerular Mesangial Cells
Published on: March 7, 2025
Comparative analysis of commercial human primary mesangial cell, implications for experimental design
Alva Johansson1, Gayathri Narasimhan1, Katharina Keuenhof1
1Institute of Neuroscience and Physiology, Department of Physiology, Sahlgrenska Academy, University of Gothenburg, Box 432, Gothenburg, 40530, Sweden.
Background:
Mesangial cells (MCs) are involved in several glomerular diseases such as IgA nephropathy and diabetic kidney disease. In vitro work on human MCs is mainly conducted on primary MCs. However, cells from different donors could be significantly different, thus potentially affecting the outcome of the experiments.
Method:
We have compared commercially available primary human MCs from two different sources: HMCv1 and HMCv2. The cells were characterized using qPCR, western blot, and immunofluorescence. Response to PDGF-BB was assessed with proliferation assays, proteomics, and qPCR. Response to angiotensin II was assessed through contractility assay and response to IL-1β, diabetic milieu and TGFβ1 with qPCR.
Results:
Cells from both sources expressed mesangial markers. HMCv1, but not HMCv2, showed significant contractility in response to angiotensin II. Both HMCv1 and 2 significantly increased their proliferation rate in response to PDGF-BB. Proteomics revealed a stronger response to PDGF-BB for HMCv1 in respect to HMCv2, though similar pathways were regulated in both. IL-1β stimulus was stronger in HMCv1 in terms of increased expression of IL6 and CCL2/MCP1 mRNA. Diabetic milieu increased expression of IL-6 for both HMCv1 and 2, but significantly higher for HMCv1. TGFβ1 gave similar results in terms of IL-6 expression for cells from both sources. In addition, a list of 144 potential mesangial markers was compiled, that can be used for identification of MCs in omics data.
Conclusion:
This study shows that there are broad differences between sources of primary human MCs. The potential differences between clones of primary MCs need to be carefully considered when conducting in vitro experiments.
Insights
Primary human mesangial cells (MCs) from different sources exhibit significant functional and molecular differences. Researchers must consider these variations when designing in vitro studies for glomerular diseases.
Area of Science:
- Nephrology
- Cell Biology
- Genomics
Background:
- Mesangial cells (MCs) are central to glomerular diseases like IgA nephropathy and diabetic kidney disease.
- In vitro research relies heavily on primary human MCs, but donor variability can impact experimental outcomes.
Purpose of the Study:
- To compare commercially available primary human MCs from two distinct sources (HMCv1 and HMCv2).
- To characterize their responses to various stimuli relevant to kidney disease.
Main Methods:
- Utilized qPCR, Western blot, and immunofluorescence for cell characterization.
- Assessed proliferation (PDGF-BB), contractility (angiotensin II), and gene expression (IL-1β, diabetic milieu, TGFβ1).
- Proteomics was employed to analyze responses to PDGF-BB.
Main Results:
- Both cell sources expressed mesangial markers; HMCv1 showed angiotensin II-induced contractility, unlike HMCv2.
- PDGF-BB increased proliferation in both, with a stronger proteomic response in HMCv1.
- HMCv1 exhibited heightened responses to IL-1β and diabetic milieu stimuli compared to HMCv2.
- Compiled a list of 144 potential mesangial markers for omics data identification.
Conclusions:
- Significant functional and molecular differences exist between primary human MCs from different commercial sources.
- Variability in primary MCs necessitates careful consideration in in vitro experimental design and interpretation.
